Ganymed Pharmaceuticals Ag

Other

Novartis Ag

Johannes Gutenberg-universität Mainz

Biontech Ag

Astellas Pharma Gmbh

Tron—translationale Onkologie an Der Universitátsmedizin Der Johannes Gutenberg—universität Mainz Gemeinnützige Gmbh

Johannes Gutenberg-universität Mainz, Vertreten Durch Den Präsidenten

Philippe Thiel

Ugur Sahin

Dirk Usener

Michael Koslowski

Gerd Helftenbein

Volker Schlüter

Özlem Türeci

Ozlem Tureci

Christoph Uherek

Harald-Gerhard Geppert

Tiancen Hu

Sandra Schneider

Gunda Brandenburg

Stefan Fritz

Anja Kristina Schröder

David Jenkins

Anja Kristina Schroder

Konstantin Petropoulos

Christy Fryer

Cristoph Uherek

Joelle Deplazes-Lauber

Tiacen Hu

Oezlem Tuereci

Anja Kristina Schroeder

The invention relates to the identification of gene products that are the result of tumor-associated expression and the nucleic acids encoding the same. The invention also relates to the therapy and diagnosis of diseases wherein these gene products are the result of an aberrant tumor-associated expression. The invention also relates to the proteins, polypeptides and peptides that are the result of tumor-associated expression and to the nucleic acids encoding the same.

Identification of surface associated antigen FLJ31461 for tumor diagnosis and therapy

The present disclosure relates to antibodies or fragments thereof that target at least one conformational epitope of a Notch 3 or mutant Notch 3 receptor; and compositions and methods of use thereof.

Antibodies against notch 3

An isolated truncated desmoglein 4 (DSG4) polypeptide splice variant of the invention is characterized by an amino acid sequence that lacks a region encoded before exon 9 or beyond exon 10 of the DSG4 gene having the polynucleotide sequence of SEQ ID NO: 75. Also disclosed is a method of diagnosing a cancer, or monitoring the course thereof, in a patient. The method comprises detecting in a tissue sample of a patient the expression of a tumor-associated antigen comprising the extracellular domain of a DSG4 polypeptide encoded by a DSG4 gene having the polynucleotide sequence of SEQ ID NO: 75, or a truncated DSG4 polypeptide splice variant characterized by an amino acid sequence that lacks a region encoded before exon 9 or beyond exon 10 of the DSG4 gene.

Identification of surface-associated antigens for tumor diagnosis and therapy

The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLD18, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder.

Monoclonal antibodies against claudin-18 for treatment of cancer

Growing community of inventors

Planegg, Germany

Philippe Thiel